Biotechnology and biopharma stocks are known for high valuations based on hopes of potentially revolutionary medicine. The sector has also seen stratospheric returns yet, financially, the stocks do not have the meat to back up these lofty multiples. This could include the companies on our list.
Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) – $173.48
Biotechnology & Medical Research
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Company’s product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
- Market Cap: $4,176,325,592
- Revenue (LTM): $2,781,230
- P/B: 5.8x
- Research and Development (LTM): $107,359,280.00
Portola Pharmaceuticals Inc. (NASDAQ: PTLA) – $44.02
Biotechnology & Medical Research
Portola Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
- Market Cap: $2,518,317,429
- Revenue (LTM): $9,583,000
- P/B: 6.8x
- Research and Development (LTM): $158,659,000.00
Juno Therapeutics Inc. (NASDAQ: JUNO) – $47.32
Biotechnology & Medical Research
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company that is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.
- Market Cap: $4,383,252,212
- Revenue (LTM): $12,461,000
- P/B: 11.8x
- Research and Development (LTM): $313,127,000.00
Neurocrine Biosciences Inc. (NASDAQ: NBIX) – $42.72
Biotechnology & Medical Research
Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine-based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders.
- Market Cap: $3,668,502,720
- Revenue (LTM): $19,769,000
- P/B: 7.8x
- Research and Development (LTM): $62,986,000.00
Anacor Pharmaceuticals Inc. (NASDAQ: ANAC) – $116.03
Biotechnology & Medical Research
Anacor Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company’s lead product candidate, AN2728, is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis.
- Market Cap: $5,452,730,645
- Revenue (LTM): $50,198,000
- P/B: 83.5x
- Research and Development (LTM): $74,124,000.00
